主动监测中MRI靶向活检与系统活检随机对照研究(ASIST)
ASIST是一项前瞻性随机多中心开放标签试验,纳入近1年内确诊GG1前列腺癌且需行确认活检的男性,随机接受12针系统活检或MRI联合系统与靶向活检,主要终点为GG≥2升级比例,结果显示加用MRI靶向活检未显著提高升级检出率。
要点
- MRI联合靶向活检较单纯系统活检未显著提高GG≥2升级检出率(p=0.7)。
- 仅2针靶向活检的升级率有低于12针系统活检的趋势(p=0.09)。
- 靶向活检可识别多数但非全部有临床意义的前列腺癌。
核心结论
- 在GG1前列腺癌主动监测人群中,MRI联合靶向活检较单纯系统活检未显著增加GG≥2升级检出率。
- 仅行2针靶向活检的升级率有低于12针系统活检的趋势(p=0.09),但差异未达统计学显著性。
- 靶向活检可识别多数但非全部有临床意义的前列腺癌。
研究设计与样本
- 前瞻性、随机、多中心、开放标签试验(NCT01354171)。
- 纳入近1年内确诊GG1前列腺癌且需行确认活检的男性,共注册296例、随机273例。
- 随机分为12针系统活检组或MRI联合系统与靶向活检组(Artemis融合靶向系统)。
- 主要终点为各组GG≥2升级比例。
主要发现
- MRI组64%存在感兴趣区。
- 意向性分析(p=0.7)和符合方案分析(p=0.4)均未见GG≥2升级率差异。
- 中心病理复核后,系统活检组36/132(27%)升级,MRI组42/127(33%)升级(p=0.3)。
- 仅靶向活检(中位2针)升级19/137(14%),系统活检(中位12针)升级31/136(23%)(p=0.09)。
- MRI组中8/127(6.5%)仅靶向活检检出GG≥2而系统活检≤GG1,10/127(7.9%)仅系统活检检出GG≥2而靶向活检≤GG1。
临床怎么用
- 在主动监测确认活检中,加用MRI靶向活检未显著提高GG≥2检出率,需结合临床决策。
- 靶向活检可识别多数但非全部有临床意义的前列腺癌,阴性靶向结果不能完全排除高级别病变。
- 各中心靶向活检升级率差异提示技术熟练度可能影响检出效果。
局限性
- 靶向活检升级率在各中心间存在显著差异,可能反映靶向活检技术熟练度不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This study aimed to determine, in men recently diagnosed with grade group 1 (GG1) prostate cancer, if magnetic resonance imaging (MRI) with targeted biopsy could identify a greater proportion of men with GG ≥2 cancer on their confirmatory biopsy compared with systematic biopsies. The study was registered with www.clinicaltrials.gov (NCT01354171). DESIGN, SETTING, AND PARTICIPANTS: This study is a prospective, randomized, multicenter, open-label trial. Eligible patients were men diagnosed with GG1 cancer within 1 yr prior to study entry in whom a confirmatory biopsy was indicated. Patients were randomized to 12-core systematic biopsy or MRI with systematic and targeted biopsy using the Artemis fusion targeting system. The primary end point was the proportion upgraded to GG ≥2 in each arm. RESULTS AND LIMITATIONS: In total, 296 men were registered and 273 randomized. Of the MRI group, 64% had a region of interest. No difference was observed in the rate of GG ≥2 upgrading (the intent-to-treat population, p=0.7, and per-protocol [PP] population, p=0.4), GG ≥2 upgrading within each stratum separately, or GG ≥3. After central pathology review, upgrading was observed in 36/132 (27%) men in the systematic biopsy arm and 42/127 (33%) men in the MRI arm (p=0.3). Upgrading was seen in 19/137 (14%) patients in the MRI arm on targeted biopsy alone (median, 2 cores) compared with 31/136 (23%) in the systematic biopsy arm (median, 12 cores; p=0.09). In the MRI arm, 8/127 (6.5%) patients had GG ≥2 disease identified on targeted biopsy, but ≤GG1 on the systematic biopsy, and 10/127 (7.9%) patients had GG ≥2 disease identified by systematic biopsy but ≤GG1 on targeted biopsy. Significant differences in upgrading on targeted biopsies were seen between sites, likely reflecting different levels of expertise with the targeted biopsy technique. CONCLUSIONS: The addition of MRI with targeted biopsies to systematic biopsies did not significantly increase the upgrading rate compared with systematic biopsy alone. Furthermore, 2-core targeted biopsies alone resulted in a nonsignificant trend to less upgrading than 12-core systematic biopsy (p=0.09). In men on active surveillance, targeted biopsies identify most, but not all, clinically significant cancers.
引用
- Klotz L, Loblaw A, Sugar L, et al. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. Eur Urol. 2018. PMID: 30017404. doi:10.1016/j.eururo.2018.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。